Balance Sheet Account Detail (Tables)

3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The following is a summary of our presented “cash and cash equivalents” and “marketable securities”:




	Cost		Foreign Currency Translation			Gross Unrealized Gains		Estimated Fair Value		Cash and Cash Equivalents		Marketable Securities
March 31, 2019
Equity securities* (see Note 7)	$	8,710	$	(3,265	)	$	27,697	$	33,142	$	—	$	33,142
Bank deposits	15,649		—			—		15,649		15,649		—
Money market funds	257,003		—			—		257,003		257,003		—
Bank CDs	87		—			—		87		—		87
Total cash and cash equivalents and marketable securities	$	281,449	$	(3,265	)	$	27,697	$	305,881	$	272,652	$	33,229
December 31, 2018
Equity securities* (see Note 7)	$	8,710	$	(2,168	)	$	39,880	$	46,422	$	—	$	46,422
Bank deposits	14,735		—			—		14,735		14,735		—
Money market funds	142,745		—			—		142,745		142,745		—
Bank CDs	86		—			—		86		—		86
Total cash and cash equivalents and marketable securities	$	166,276	$	(2,168	)	$	39,880	$	203,988	$	157,480	$	46,508

* Beginning January 1, 2018, under the requirements of ASU 2016-01, Recognition and Measurement of Financial Assets and Liabilities, the unrealized (loss) gain on our CASI equity securities are recognized as an (decrease) increase to “other (expense) income, net” on the Condensed Consolidated Statements of Operations (rather than through “other comprehensive loss” on the Condensed Consolidated Statements of Comprehensive Loss). Our adoption of ASU 2016-01 on January 1, 2018 resulted in a $17.2 million cumulative-effect adjustment, net of income tax, recorded as a decrease to “accumulated other comprehensive loss” and a decrease to “accumulated deficit” on the accompanying Condensed Consolidated Balance Sheets. Our recognized unrealized (loss) gain on these equity securities for the three months ended March 31, 2019 and 2018 was $(12.2) million and $10.2 million, respectively, as reported in “other (expense) income, net” on the accompanying Condensed Consolidated Statements of Operations.

Schedule of Property and Equipment Net of Accumulated Depreciation

“Property and equipment, net of accumulated depreciation” consists of the following:



	March 31, 2019			December 31, 2018
Computer hardware and software	$	3,075		$	3,079
Laboratory equipment	669			635
Office furniture	227			212
Leasehold improvements	2,957			2,957
Property and equipment, at cost	6,928			6,883
(Less): Accumulated depreciation	(6,462		)	(6,498		)
Property and equipment, net of accumulated depreciation	$	466		$	385

Prepaid Expenses and Other Assets

“Prepaid expenses and other assets” consists of the following:



	March 31, 2019		December 31, 2018
Deposits and other	$	6,760	$	6,792
Value of equity forward-sale contract (see Note 7)	793		—
Prepaid insurance	402		782
Prepaid expenses and other assets	$	7,955	$	7,574

Schedule of Other Receivables

“Other receivables” consists of the following:



	March 31, 2019		December 31, 2018
FDA refund due	$	1,941	$	—
Other miscellaneous receivables (including Medicaid rebate credits and royalty receivables from licensees)	1,575		1,189
Income tax receivable - current portion	643		643
Insurance receivable	1,576		206
Secured promissory note (see Note 7)	1,527		1,525
Reimbursements due from development partners for incurred research and development expenses	204		135
Other receivables	$	7,466	$	3,698

Summary of Other Assets

“Other assets” consists of the following:



	March 31, 2019		December 31, 2018
Key employee life insurance – cash surrender value associated with deferred compensation plan (Note 9(f))	$	7,270	$	6,274
Income tax receivable - non-current portion*	668		668
Research & development supplies and other	242		246
Other assets	$	8,180	$	7,188

* This value represents the non-current portion of the refundable alternative minimum tax credit that is expected to be received over the next few years (see Note 10).

Assets And Liabilities, Leases

“Facility and equipment under lease” consists of the following:



	March 31, 2019		December 31, 2018
Office and research facilities	$	3,287	$	—
Office equipment	487		—
Facility and equipment under lease (Note 9(a))	$	3,774	$	—

The below table summarizes these lease asset and liability accounts presented on our accompanying Condensed Consolidated Balance Sheets:



Operating Leases*	Condensed Consolidated Balance Sheet Caption	Balance at March 31, 2019
Operating lease right-of-use assets - non-current	Facility and equipment under lease	$	3,774

Operating lease liabilities - current	Accounts payable and other accrued liabilities	$	808
Operating lease liabilities - non-current	Other long-term liabilities	3,114
Total operating lease liabilities		$	3,922

* As of March 31, 2019, we have no “finance leases” as defined in Topic 842.

Schedule of Accounts Payable and Other Accrued Liabilities

“Accounts payable and other accrued liabilities” consists of the following:



	March 31, 2019		December 31, 2018
Trade accounts payable and other	$	41,788	$	44,919
Lease liability - current portion (Note 9(a))	808		—
Accrued commercial/Medicaid rebates	6,370		8,371
Accrued product royalty due to licensors	1,910		4,337
Allowance for product returns	5,325		5,171
Accrued data and distribution fees	2,398		3,248
Accrued GPO administrative fees	150		296
Accrued inventory management fees	368		388
Allowance for government chargebacks	1,185		2,730
Accounts payable and other accrued liabilities	$	60,302	$	69,460

Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities

Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Condensed Consolidated Balance Sheets for our categories of GTN estimates (see Note 2(i)) were as follows:



	Commercial/Medicaid Rebates and Government Chargebacks			Distribution, Data, Inventory and GPO Administrative Fees			Product Return Allowances
Balance as of December 31, 2017	$	10,358		$	5,727		$	4,045
Add: GTN accruals recorded for product sales	65,751			13,962			1,700
(Less): Payments made and credits against GTN accruals	(65,008		)	(15,757		)	(574		)
Balance as of December 31, 2018	$	11,101		$	3,932		$	5,171
Add: GTN accruals recorded for product sales	5,452			12			167
(Less): Payments made and credits against GTN accruals	(8,998		)	(1,028		)	(13		)
Balance as of March 31, 2019	$	7,555		$	2,916		$	5,325

Deferred Revenue, by Arrangement, Disclosure

“Contract liabilities” consists of the following:



	March 31, 2019		December 31, 2018
Customer deposit for EVOMELA supply in China territory (see Note 7)	$	4,850	$	4,850
Contract liabilities	$	4,850	$	4,850

Summary of Other Long-Term Liabilities

“Other long-term liabilities” consists of the following:



	March 31, 2019		December 31, 2018
Deferred compensation liability (Note 9(f))	$	6,499	$	5,474
Lease liability - non-current portion (Note 9(a))	3,114		—
Other tax liabilities	176		176
Other long-term liabilities	$	9,789	$	5,650